NOT FOR DISSEMINATION IN THE UNITED STATES OF AMERICA

VentriPoint Diagnostics Ltd. (the "Corporation") (TSX VENTURE:VPT) today
announced the initial closing of its secured debenture offering (the "Offering")
and the submission of the comprehensive Technical File by its wholly-owned
subsidiary, VentriPoint, Inc. ("VentriPoint") in its efforts to receive
CE-marking to permit the marketing of its VentriPoint Medical System ("VMS") in
Europe. The VMS provides key measurements and accurate 3-D reconstructions of
the right ventricle of a patient's heart from standard two-dimensional
ultrasound images.


Joe Ashley, President & CEO of the Corporation, explained, "With the very
difficult financing environment in which we have found ourselves, we are
extremely pleased and grateful to those investors who have recognized the
importance of our solution to patients with heart disease and are supporting our
efforts as we transition into the exciting commercialization phase of our
growth. The net proceeds of the initial closing of $236,000 will provide
operational capital to pursue regulatory approvals and to commence
implementation of our commercialization plans that will bring the VMS heart
diagnostic and monitoring tool to market. Another closing of the Offering is
being scheduled."


VentriPoint has engaged Intertek Semko AB as its Notified Body to conduct the
third-party conformity assessment procedures as required by the Medical Device
Directive recognized by the 30 member states of the European Economic Area.
Pursuant with this engagement, VentriPoint has submitted its comprehensive
Technical File which incorporates its previously announced ISO 13485:2003
certification. A positive conclusive review by Intertek Semko AB will provide
VentriPoint with a CE-mark to permit the marketing and selling of the
VentriPoint Medical System within select European Countries.


About VentriPoint Diagnostics Ltd.

VentriPoint creates diagnostic tools to monitor patients with heart disease -
the number one cause of death in developed countries. By using images produced
from existing medical imaging systems, the VentriPoint Medical System ("VMS")
generates critical heart measurements in a rapid and inexpensive manner not
currently available. Health Canada has granted licensed approval for the VMS
breakthrough diagnostic tool which is based upon technology received by
VentriPoint through its exclusive technology license with the University of
Washington. The VMS, together with its associated online service, is being
expanded to cover a variety of heart related disease states, including
congenital heart disease and pulmonary hypertension.


To receive press release, please email chris@chfir.com and mention VentriPoint
in the subject line.


FORWARD-LOOKING STATEMENTS: The statements made in this press release that are
not historical facts contain forward-looking information that involves risk and
uncertainties. All statements, other than statements of historical facts, which
address VentriPoint's expectations, should be considered forward-looking
statements. Such statements are based on management's exercise of business
judgment as well as assumptions made by and information currently available to
management. When used in this document, the words "may", "will", "anticipate",
"believe", "estimate", "expect", "intend" and words of similar import, are
intended to identify any forward-looking statements. You should not place undue
reliance on these forward-looking statements. These statements reflect a current
view of future events and are subject to certain risks and uncertainties as
contained in the Corporation's filings with Canadian securities regulatory
authorities. Should one or more of these risks or uncertainties materialize, or
should underlying assumptions prove incorrect, actual results could differ
materially from those anticipated in these forward-looking statements. The
Corporation undertakes no obligation, and does not intend, to update, revise or
otherwise publicly release any revisions to these forward-looking statements to
reflect events or circumstances after the date hereof, or to reflect the
occurrence of any unanticipated events. Although management believes that
expectations are based on reasonable assumptions, no assurance can be given that
these expectations will materialize.
Vortex Metals (TSXV:VMS)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Vortex Metals Charts.
Vortex Metals (TSXV:VMS)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Vortex Metals Charts.